Related Experiment Video

Updated: Oct 2, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.2K

PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced

Meidi Utami Puteri1, Nuriza Ulul Azmi1,2,3, Mitsuyasu Kato3

  • 1Department of Pharmacology-Toxicology, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.

Life (Basel, Switzerland)
|February 25, 2022
PubMed

Insights

Proprotein convertase subtilisin/kexin type 9 (PCSK9) influences lipid metabolism and platelet activation. Understanding PCSK9’s role in atherosclerosis-related myocardial infarction offers new therapeutic targets for cardiovascular disease.

Area of Science:

  • Cardiovascular biology
  • Molecular medicine
  • Thrombosis research

Background:

  • Cardiovascular diseases, particularly myocardial infarction (MI), are a leading global cause of mortality.
  • Atherosclerosis is a primary driver of MI, necessitating research into preventative strategies.
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) is known to regulate low-density lipoprotein (LDL) receptor degradation and lipid metabolism.

Purpose of the Study:

  • To explore the role of PCSK9 in platelet activation within the context of atherosclerosis-induced MI.
  • To elucidate the molecular mechanisms by which PCSK9 regulates platelet activation.
  • To identify potential new therapeutic strategies for cardiovascular disease progression.

Main Methods:

  • Review of current experimental studies and literature on PCSK9, lipid metabolism, and platelet function.
  • Analysis of the pathophysiological processes in atherosclerosis-induced MI.
  • Highlighting molecular mechanisms of PCSK9 in platelet regulation.

Main Results:

  • PCSK9 plays a role in lipid metabolism by promoting LDL receptor degradation.
  • Emerging evidence suggests PCSK9 is involved in platelet activation during atherosclerosis.
  • Limited studies currently focus on PCSK9's specific role in platelet activation.

Conclusions:

  • A deeper understanding of PCSK9's molecular mechanisms in platelet activation is crucial for MI.
  • Targeting PCSK9 pathways involved in platelet function may offer novel therapeutic approaches.
  • Further research into PCSK9 and platelet interaction could advance cardiovascular disease treatment.

Keywords:
atherogenesisatherosclerosisatherothrombosiscardiovascular diseasecluster of differentiation 36myocardial infarctionplatelet activationproprotein convertase subtilisin/kexin type 9

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

678

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
200
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
70
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
680
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
58
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
53
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
67